Frazier Life Sciences Management, L.P. Arcutis Biotherapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.67 Billion
- Q4 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 8,785,284 shares of ARQT stock, worth $138 Million. This represents 7.34% of its overall portfolio holdings.
Number of Shares
8,785,284
Previous 8,785,284
-0.0%
Holding current value
$138 Million
Previous $81.7 Million
49.79%
% of portfolio
7.34%
Previous 4.4%
Shares
4 transactions
Others Institutions Holding ARQT
# of Institutions
219Shares Held
129MCall Options Held
2.02MPut Options Held
202K-
Jennison Associates LLC12.3MShares$194 Million0.11% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.4MShares$179 Million6.61% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$173 Million2.52% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$136 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X07.38MShares$116 Million0.63% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $947M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...